An examination of how retatrutide’s glucagon receptor agonism drives cAMP-PKA signaling in hepatocytes, modulates CPT1A-mediated beta-oxidation, and suppresses SREBP-1c and ChREBP lipogenic gene programs in preclinical metabolic steatosis research.

An examination of retatrutide’s glucagon receptor component and its role in activating the cAMP-PKA-PGC-1alpha-UCP1 thermogenic cascade in brown adipose tissue in preclinical research models.